AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Wednesday 11 November 2026
News from the 24 hours to Wednesday morning, 11 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by the acquisition of vaccine start-up Omniose, which adds a bioconjugation platform to the vaccine pipeline. Positive items also included the EU approval for Enhertu, an expanded SAP partnership and reaffirmed guidance.
What drove it
- Omniose acquisition
- Enhertu EU approval
- SAP partnership
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 5 Nov | +6.3 | 24 |
| Fri 6 Nov | +4.0 | 37 |
| Sat 7 Nov | +4.5 | 9 |
| Sun 8 Nov | +6.0 | 7 |
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
8 stories · 22 headlines · strongest first
Pharma and healthcare on 11 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca acquires US biotech Omniose +7.49 headlines today · 21 in all · Many outlets report AstraZeneca buying Omniose, adding a bioconjugation vaccine platform. | ||
| +7.0 | Acquisition of US biotech adds to its vaccine pipeline. | |
| +7.0 | Deal advances its bacterial vaccine research. | |
| +6.7 | Buying existing partner secures bacterial vaccine technology. | |
| +6.7 | Takeover adds a bioconjugation technology to vaccine research. | |
| +6.7 | Acquisition of vaccine startup expands its vaccine capabilities. | |
| +6.7 | Deal brings a bioconjugate vaccine technology platform in-house. | |
| +6.7 | Purchase of a St. Louis vaccine developer strengthens its portfolio. | |
| +6.3 | Target company confirms being bought by AstraZeneca. | |
| +6.3 | Purchase of US biotech company announced. | |
| AstraZeneca expands SAP collaboration +4.25 headlines today · AstraZeneca is reported to be shifting its ERP over to SAP's cloud and using its AI tools. | ||
| +5.0 | Broader software collaboration to adopt cloud and AI tools. | |
| +5.0 | Wider software partnership to modernise operations and support AI. | |
| +4.2 | Operations moving to cloud software while share repurchases continue. | |
| +4.2 | Major cloud migration and ongoing share repurchases. | |
| +2.5 | AstraZeneca named as new SAP cloud customer, minor positive mention in roundup.}, { | |
| EU approves Enhertu for AstraZeneca +7.92 headlines today · Reports say an EU Enhertu approval put AstraZeneca's valuation back in focus. | ||
| +8.3 | European approval widens use of a key cancer drug. | |
| +7.5 | Regulatory approval for cancer drug refocuses attention on valuation. | |
| AstraZeneca analyst target changes and guidance +6.82 headlines today · 8 in all · Pieces discuss mixed analyst target changes and reaffirmed guidance. | ||
| +5.0 | Guidance maintained and pipeline seen as strong, with valuation upside. | |
| +0.8 | Analyst targets split, valuation estimate slightly higher. | |
| AstraZeneca ranked third in Access to Medicine Index +5.81 headline today · AstraZeneca announces its third-place ranking in the 2026 index. | ||
| +5.8 | Strong placing in an access-to-medicine ranking helps reputation. | |
| AstraZeneca awards $1.6m for US healthcare access programmes +4.21 headline today · 2 in all · AstraZeneca announces $1.6 million in awards for programmes improving US healthcare access. | ||
| +3.3 | Small funding grants supporting healthcare access, reputational plus. | |
| AstraZeneca BioVentureHub profiled +2.51 headline today · An article looks inside AstraZeneca's BioVentureHub. | ||
| +2.5 | Feature on its innovation hub supporting start-ups. | |
| Sylvana Hassanieh takes AstraZeneca gynaecological oncology role +0.81 headline today · Sylvana Hassanieh announces a new global medical affairs leader role at AstraZeneca. | ||
| +0.8 | Routine senior appointment within its oncology medical affairs team. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.